JPRN-jRCT2071220098进行中（未招募）1 期
A Phase 1, open-label, randomized, parallel, study to evaluate the pharmacokinetics, safety, and tolerability of single-dose SAR441344 in healthy adult Chinese and Japanese male and female participants
Tanaka Tomoyuki0 个研究点目标入组 36 人开始时间: 2023年1月31日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 36
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 <= 45age old（—）
- 性别
- All
入选标准
- •East Asian (ethnic Chinese or Japanese) adult male or female participants, between 20 and 45 years of age, inclusive, at the time of signing the informed consent.
- •- Participants who are overtly healthy as determined by medical evaluation including medical history, physical examination, and laboratory tests.
- •- Laboratory parameters within the normal range (or defined screening threshold for the Investigator site), unless the Investigator considers an abnormality to be clinically
- •irrelevant for healthy participant.
- •- Body weight within the range from 50 to 100 kg, inclusive, if male; and between 45 and 90 kg, inclusive, if female; body mass index (BMI) within the range from 18.0 to 30.0 kg/m^2, inclusive.
- •- Contraceptive used by men and women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies. A female participant is eligible to participate if she is not pregnant or breastfeeding.
- •- Capable of giving signed informed consent with the requirements and restrictions listed in the informed
- •consent form (ICF) and in this protocol.
排除标准
- •Participants are excluded from the study if any of the following criteria apply:
- •Medical conditions
- •- Any history or presence of clinically relevant immunologic, cardiovascular, pulmonary, gastrointestinal, hepatic, renal, metabolic, hematological, neurological, osteomuscular, articular, psychiatric, systemic, ocular, gynecologic (if female), or infectious disease, or signs of acute illness.
- •- Frequent headaches and/or migraine, recurrent nausea and/or vomiting (for vomiting only: more than twice a month).
- •- Blood donation, any volume, within 2 months before inclusion (Note: For a site in Japan, blood donation of 400 mL within 12 weeks [for male] or 16 weeks [for female], 200 mL within 4 weeks or apheresis donation within 2 weeks before the first IMP administration).
- •- Symptomatic postural hypotension, irrespective of the decrease in blood pressure, or asymptomatic postural hypotension defined as a decrease in systolic blood pressure >=20 mmHg within 3 minutes when changing from supine to standing position.
- •- Presence or history of drug hypersensitivity, or allergic disease diagnosed and treated by a physician.
- •- History or presence of drug or alcohol abuse.
- •Prior/concomitant therapy
- •- Any medication within 14 days before inclusion or within 5 times the elimination half-life or PD half-life of the medication (whichever is longer), with the exception of hormonal contraceptives.
- •- Participant must not have received any vaccination within the 4 weeks before inclusion and should adhere to vaccination restrictions for the study (ie, participant may not receive any vaccines from inclusion to EOS).
- •Other exclusions
- •- Participant not suitable for participation, whatever the reason, as judged by the Investigator, including medical or clinical conditions, or participants potentially at risk of noncompliance to study procedures.
- •The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
研究者
相似试验
进行中（未招募）
1 期
Pharmacokinetics, safety, and tolerability of a single-dose of SAR443765 in healthy Japanese participantsJPRN-jRCT2071220112Tanaka Tomoyuki12
进行中（未招募）
1 期
A Phase 1, open label study to evaluate the pharmacokinetics, safety and tolerability of single subcutaneous dose amlitelimab in healthy adult participants.JPRN-jRCT2071220049Tanaka Tomoyuki24
已完成
Unknown
A parallel, Phase 1, randomized, open label study to evaluate the pharmacokinetics, safety and tolerability of single subcutaneous dose amlitelimab in healthy Chinese and Japanese adult participants.KCT0008635Sanofi-Aventis Korea24
已完成
不适用
A phase 1, two-part, randomized, open-label study to evaluate the relative bioavailability and food effect of test formulations of VX-152 and Ivacaftor in healthy subjects10038686Cystic FibrosisNL-OMON43101Vertex Pharmaceuticals30
进行中（未招募）
1 期
Effect of SARS-CoV-2 Equine Antiserum Immunoglobulin (Purified F(ab)2 fragment) in hospitalised COVID-19 patients with moderate disease.CTRI/2020/11/028779Biological ELimited